United Therapeutics (NASDAQ:UTHR) Stock Falls 4.1% Following Insider Selling

United Therapeutics Corporation (NASDAQ:UTHR) dropped 4.1% during trading on Friday after an insider sold shares in the company. The stock traded as low as $547.63 and last traded at $548.1420. 122,396 shares traded hands during trading, a decline of 77% from the average daily volume of 535,885 shares. The stock had previously closed at $571.38.

Specifically, CEO Martine Rothblatt sold 7,580 shares of the firm’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $517.97, for a total value of $3,926,212.60. Following the completion of the sale, the chief executive officer directly owned 326,363 shares of the company’s stock, valued at $169,046,243.11. This trade represents a 2.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine Rothblatt sold 1,920 shares of the stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $550.22, for a total value of $1,056,422.40. Following the sale, the chief executive officer owned 324,443 shares in the company, valued at $178,515,027.46. The trade was a 0.59% decrease in their position. The disclosure for this sale is available in the SEC filing. In other United Therapeutics news, EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $564.95, for a total transaction of $4,689,085.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $25,519,921.40. The trade was a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research note on Thursday, August 6th. Bank of America dropped their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a report on Friday, July 10th. The Goldman Sachs Group initiated coverage on United Therapeutics in a research note on Thursday, September 24th. They issued a “sell” rating and a $321.00 target price on the stock. Royal Bank Of Canada lowered their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Finally, Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $621.00.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: A Delaware federal court found that Liquidia’s Yutrepia infringes two United Therapeutics patents covering inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The court also rejected Liquidia’s arguments that the patents were invalid, strengthening the competitive position of UTHR’s Tyvaso franchise. United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
• Positive Sentiment: The ruling could restrict Yutrepia’s use in the PH-ILD market and potentially support a request for the FDA to withdraw or limit that indication until revised labeling is approved. Investors are viewing the decision as a potential extension of Tyvaso’s market protection and future cash-flow durability. UTHR Prevails in LQDA’s Yutrepia Patent Dispute
• Positive Sentiment: Analyst sentiment remains broadly constructive, with some firms maintaining targets well above the current share price. The company’s patent win and the resulting collapse in Liquidia shares reinforced expectations of reduced competitive pressure. United Therapeutics Stock Rises Following Federal Court Patent Victory
• Neutral Sentiment: The legal outcome may still face appeals, additional proceedings, or regulatory review, so the timing and financial impact of any restrictions on Yutrepia remain uncertain. Analysts also have conflicting views, ranging from a bullish $687 target to a bearish $321 target, highlighting valuation and execution risk. Analysts Have Conflicting Sentiments on Healthcare Companies
• Negative Sentiment: Insider selling provides a counterpoint: CEO Martine Rothblatt sold a combined 9,500 shares, while EVP Paul Mahon sold 8,300 shares worth approximately $4.7 million. These sales may reflect scheduled trading plans, but continued insider selling could weigh on sentiment. United Therapeutics Insider Selling

United Therapeutics Stock Down 4.1%

The company’s 50 day moving average price is $510.03 and its 200 day moving average price is $539.64. The firm has a market capitalization of $23.51 billion, a price-to-earnings ratio of 19.71, a P/E/G ratio of 2.72 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same quarter last year, the business posted $6.41 EPS. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. As a group, analysts expect that United Therapeutics Corporation will post 26.21 earnings per share for the current year.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in UTHR. QRG Capital Management Inc. grew its position in United Therapeutics by 3.5% during the 2nd quarter. QRG Capital Management Inc. now owns 3,476 shares of the biotechnology company’s stock worth $1,883,000 after purchasing an additional 116 shares during the period. Envestnet Portfolio Solutions Inc. grew its position in shares of United Therapeutics by 1.8% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 3,445 shares of the biotechnology company’s stock valued at $1,867,000 after acquiring an additional 60 shares during the period. Andra AP fonden increased its position in shares of United Therapeutics by 33.5% in the second quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company’s stock valued at $18,912,000 after buying an additional 8,760 shares in the last quarter. Security National Bank of SO Dak purchased a new stake in United Therapeutics in the 2nd quarter worth $179,000. Finally, Talon Private Wealth LLC raised its position in United Therapeutics by 31.8% during the second quarter. Talon Private Wealth LLC now owns 6,753 shares of the biotechnology company’s stock worth $3,659,000 after acquiring an additional 1,630 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.